natgillin/translations-raw huggingface dataset:
Doses may be delayed or reduced by the doctor, or treatment may be stopped, if severe side effects occur; doses should also be reduced in patients with moderate or severe reduction in liver function.
Če se pojavijo resni neželeni učinki, lahko zdravnik odmerek preloži ali zmanjša oziroma zdravljenje ustavi; odmerke je treba prav tako zmanjšati pri bolnicah z zmernimi ali hudimi motnjami delovanja jeter.
Apealea must not be used in patients who are breast feeding or those who already have low levels of neutrophils in the blood.
Zdravila Apealea ne smejo uporabljati doječe matere in osebe, ki že imajo nizko število nevtrofilcev.
Apealea is available as a powder to make up a solution for infusion (drip) into a vein.
Zdravilo Apealea je na voljo v obliki praška za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
Apealea is a cancer medicine used to treat women with cancer of the ovary or surrounding structures (the fallopian tube that connects the ovary to the womb, or the peritoneum, the membrane that lines the abdomen).
Apealea je zdravilo za zdravljenje raka, ki se uporablja pri odraslih ženskah z rakom jajčnikov ali sosednjih struktur (jajcevodov, ki povezujejo jajčnike z maternico) in peritonelanega raka (raka membrane, ki ovija trebušno votlino).
Apealea is given along with a platinum-based medicine, carboplatin, to patients whose disease responds to platinum-based cancer medicines and has come back after initial treatment.
Zdravilo Apealea se daje skupaj z zdravilom na osnovi platine, karboplatinom, in sicer bolnicam, katerih rak se odziva na zdravila za zdravljenje raka na osnovi platine in se je ponovil.
Patients are also treated with a platinum-based medicine, carboplatin.
Bolnice se zdravijo tudi z zdravilom na osnovi platine, karboplatinom.
Apealea contains the active substance paclitaxel.
Zdravilo Apealea vsebuje učinkovino paklitaksel.
For the full list of side effects of Apealea, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Apealea, glejte navodilo za uporabo.
How is Apealea used?
Kako se zdravilo Apealea uporablja?
Patients also received a platinum-based cancer medicine, carboplatin.
Bolnice so prejele tudi zdravilo na osnovi platine, karboplatin.
The paclitaxel in Apealea is formulated in tiny particles, called micelles, to help it dissolve in the infusion solvent.
Učinkovina paklitaksel v zdravilu Apealea je v obliki majhnih delcev, imenovanih micele, ki pripomorejo k boljšemu topljenju v topilu za infundiranje.
How does Apealea work?
Kako zdravilo Apealea deluje?
-1 Live avian infectious bronchitis virus, strain D388: 104.0 - 105.5 EID50*/dose * 50% egg infective dose
-1 živi virus kužnega bronhitisa za perutnino D388 104.0 - 105.5 EID50*/odmerek 1 50-odstotni odmerek za embrionirana kokošja jajca
-1 Lyophilisate and solvent for oculonasal suspension
-1 Liofilizat in topilo za okulonazalno suspenzijo
Solvent: 35 ml
Topilo 35 ml
Solvent: vial (LDPE)
Topilo: viala (LDPE)
10 lyophilisate cups + 10 solvent vials
10 vsebnikov liofilizata + 10 vial topila
EU (MA) number Invented name
EU številka Izmišljeno ime Jakost Farmacevtska oblika
Lyophilisate: 1,000 doses
Liofilizat: 1000 odmerkov
Packaging Content Package size Withdrawal period
Velikost pakiranja
10 cups
Ovojnina
Chicken Oculonasal use Lyophilisate: cup (Alu/PP);
Liofilizat: vsebnik (Al/PP)
It is available as tablets (2.5, 5, 10 and 20 mg).
Na voljo je v obliki tablet (2,5, 5, 10 in 20 mg).
The main measure of effectiveness was the improvement in symptoms after 12 weeks.
Glavno merilo učinkovitosti je bilo izboljšanje simptomov po 12 tednih.
The European Commission granted a marketing authorisation valid throughout the European Union for Cialis on 12 November 2002.
Evropska komisija je dovoljenje za promet z zdravilom Cialis, veljavno po vsej Evropski uniji, izdala 12. novembra 2002.
What measures are being taken to ensure the safe and effective use of Cialis?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Cialis?
A doctor should consider the potential risks of sexual activity in men who have cardiovascular disease.
Zdravnik mora upoštevati morebitna tveganja pri spolni aktivnosti moških, ki imajo srčno-žilne bolezni.
The full EPAR for Cialis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Cialis je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Cialis.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Cialis.
A risk management plan has been developed to ensure that Cialis is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Cialis je bil pripravljen načrt obvladovanja tveganj.
For more information about treatment with Cialis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Cialis preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Other information about Cialis
Druge informacije o zdravilu Cialis
The CHMP decided that Cialis's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Cialis večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Once-a-day dosing of Cialis was studied in three further studies lasting 12 to 24 weeks and involving a total of 853 patients.
Enkrat dnevno odmerjanje zdravila Cialis so nadalje proučevali v treh dodatnih študijah, ki so trajale od 12 do 24 tednov in v katerih je sodelovalo skupaj 853 bolnikov.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cialis.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What benefit has Cialis shown during the studies?
Kakšne koristi je zdravilo Cialis izkazalo med študijami?
Overall, in the studies of general populations, 81% of patients reported that Cialis ‘on demand' improved their erections as compared to 35% of those taking placebo.
Na splošno je v študijah, izvedenih med splošno populacijo, 81 % bolnikov poročalo, da je zdravilo Cialis, vzeto „po potrebi“, izboljšalo njihovo erekcijo, v primerjavi s 35 % bolnikov, ki so jemali placebo.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom medicine should be taken around the same time every day and the appropriateness of the once-a-day dosing should be re-assessed regularly.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom dobro ga bolnik prenaša.
Because Cialis has not been studied in patients who have had a heart attack within the last three months or a stroke within the last six months, or those who have high blood pressure or heart disorders (irregular heart beat), these men should not use the medicine.
Zdravilo Cilais ni bilo raziskano pri bolnikih, ki so v zadnjih treh mesecih doživeli srčni infarkt ali možgansko kap v zadnjih šestih mesecih, ali pri bolnikih, ki imajo visok krvni tlak ali srčna obolenja (nepravilno bitje srca), zato ti bolniki zdravila ne smejo uporabljati.
One of these studies contained only diabetic men.
V eni študiji so sodelovali samo moški s sladkorno boleznijo.
It must also not be taken by patients who have ever had loss of vision because of a problem with blood flow to the nerve in the eye (non-arteritic anterior ischemic optic neuropathy, NAION).
Prav tako ga ne smejo jemati bolniki, ki so kadar koli imeli težave z vidom zaradi dotoka krvi v očesni živec (nearteritična anteriorna ishemična optična nevropatija ali NAION).
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Cialis, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Patients taking Cialis once a day at doses of 2.5 or 5 mg also reported improved erections compared with those taking placebo.
Tudi bolniki, ki so zdravilo Cialis jemali enkrat na dan v odmerku 2,5 ali 5 mg, so poročali o izboljšanju erekcije v primerjavi s tistimi, ki so jemali placebo.
In all studies, the effects of Cialis were compared with those of placebo (a dummy treatment), and the main measure of effectiveness was the ability to get and maintain an erection.
V vseh študijah so učinke zdravila Cialis primerjali z učinki placeba (zdravila brez zdravilne učinkovine), glavno merilo učinkovitosti pa je bila sposobnost doseči in obdržati erekcijo.
For one of the questionnaires, where the maximum score is 30, patients who recorded scores of about 15 before treatment, recorded scores of 22.6 or 25 after receiving Cialis 10 mg or 20 mg, respectively.
V enem od vprašalnikov, kjer je bilo najvišje možno število točk 30, so bolniki, ki so imeli pred zdravljenjem 15 točk, po jemanju 10-miligramskega odmerka zdravila Cialis dosegli 22,6 točk oziroma 25 točk po jemanju 20-miligramskega odmerka.
The most common side effects with Cialis are headache, dyspepsia (indigestion), back pain and myalgia (muscle pain), which are more common at higher doses.
Najpogostejši neželeni učinki zdravila Cialis so glavobol, dispepsija (prebavne motnje), bolečine v hrbtu in mialgija (bolečine v mišicah), ki pa so pogostejši pri večjih odmerkih.
What is the risk associated with Cialis?
Kakšna tveganja so povezana z zdravilom Cialis?
Cialis given at a dose of 5 mg was also more effective than placebo in all the studies in patients with benign prostatic hyperplasia, with the results showing a significant improvement in symptoms after 12 weeks compared with placebo.
Prav tako je bilo zdravilo Cialis, vzeto v 5-miligramskem odmerku, učinkovitejše od placeba v vseh študijah z bolniki z benigno hiperplazijo prostate, pri čemer so rezultati pokazali na znatno izboljšanje simptomov po 12 tednih v primerjavi s placebom.
Cialis is used to treat men with erectile dysfunction (sometimes called impotence) when they cannot get, or keep, a hard penis (erection) sufficient for satisfactory sexual activity.
Zdravilo Cialis se uporablja za zdravljenje erektilne disfunkcije (imenovane tudi impotenca) pri moških, kadar ne zmorejo doseči ali ohraniti takšne erekcije penisa, ki omogoča zadovoljivo spolno aktivnost.
The active substance of Cialis, tadalafil, belongs to a group of medicines called 'phosphodiesterase type 5 (PDE5) inhibitors'.
Zdravilna učinkovina v zdravilu Cialis, tadalafil, spada v skupino zdravil imenovanih zaviralci fosfodiesteraze tipa 5 (PDE5).
For treating erectile dysfunction, the recommended dose of Cialis is 10 mg taken ‘on demand' at least 30 minutes before sexual activity.
Priporočeni odmerek zdravila Cialis za zdravljenje erektilne disfunkcije je 10 mg, vzame pa se „po potrebi“ vsaj 30 minut pred spolno aktivnostjo.
It works by blocking the phosphodiesterase enzyme, which normally breaks down a substance known as cyclic guanosine monophosphate (cGMP).
Deluje tako, da zavira encim fosfodiesterazo, ki običajno razgrajuje snov, imenovano ciklični gvanozin-monofosfat (cGMP).
During normal sexual stimulation, cGMP is produced in the penis, where it causes the muscle in the spongy tissue of the penis (the corpora cavernosa) to relax, allowing the flow of blood into the corpora, producing the erection.
Med normalno spolno stimulacijo cGMP nastaja v penisu, kjer povzroči, da se gobasto tkivo penisa (corpora cavernosa) sprosti, kar omogoči dotok krvi v tkivo in posledično erekcijo.
Cialis is a medicine containing the active substance tadalafil.
Cialis je zdravilo, ki vsebuje zdravilno učinkovino tadalafil.
By blocking the phosphodiesterase enzyme and preventing the breakdown of cGMP, Cialis also improves the blood flow to, and relaxes the muscles of, the prostate and bladder.
Z zaviranjem encima fosfodiesteraze in preprečevanjem razgradnje cGMP zdravilo Cialis prav tako izboljša pretok krvi v prostato in mehur ter sprosti tamkajšnje mišice.
Cialis must not be taken with nitrates (a type of medicine used for angina) or medicines of the class ‘guanylate cyclase stimulators' such as riociguat (a medicine for high blood pressure in the vessels supplying the lungs, known as pulmonary hypertension).
Zdravilo se ne sme jemati z nitrati (vrsto zdravil za zdravljenje angine pektoris) ali z zdravili razreda spodbujevalcev gvanilat ciklaze, kot je riocigvat (zdravilo za zdravljenje pljučne hipertenzije, tj. visokega krvnega pritiska v krvnih žilah, ki oskrbujejo pljuča).
For treating men with benign prostatic hyperplasia, or men with both benign prostatic hyperplasia and erectile dysfunction, the recommended dose is 5 mg once a day.
Priporočeni odmerek za zdravljenje moških z benigno hiperplazijo prostate ali moških z benigno hiperplazijo prostate in erektilno disfunkcijo je 5 mg enkrat na dan.
Four main studies comparing Cialis with placebo were carried out in 1,500 patients with the condition, including some who also had erectile dysfunction.
Izvedene so bile štiri glavne študije, v katerih so zdravilo Cialis primerjali s placebom pri 1 500 bolnikih s to boleznijo, vključno z nekaterimi, ki so imeli poleg tega tudi erektilno disfunkcijo.
Cialis can also be used in men to treat the signs and symptoms of benign prostatic hyperplasia (enlarged prostate gland that is not cancerous), which involve problems with the flow of urine.
Zdravilo se lahko uporablja tudi za zdravljenje znakov in simptomov benigne hiperplazije prostate (povečane prostate, ki ni rakava) pri moških, kar vključuje težave v pretoku urina.
Why has Cialis been approved?
Zakaj je bilo zdravilo Cialis odobreno?
Cialis has also been studied in patients with benign prostatic hyperplasia.
Zdravilo Cialis so proučevali tudi pri bolnikih z benigno hiperplazijo prostate.
For the full list of all side effects reported with Cialis, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Cialis, glejte navodilo za uporabo.
Cialis was significantly more effective than placebo in all studies in erectile dysfunction.
Zdravilo Cialis je bilo v vseh študijah erektilne disfunkcije znatno učinkovitejše od placeba.
However, sexual stimulation is still needed.
Za učinkovitost zdravila v tem stanju je potrebna spolna stimulacija.
Once-a-day dosing is not recommended in patients with severe kidney problems, and should only be prescribed to patients with liver problems after a careful evaluation of the benefits and risks of taking the medicine.
Bolniki z resnimi obolenji jeter ali ledvic ne smejo jemati odmerkov, večjih od 10 mg. Odmerjanje zdravila enkrat na dan ni priporočljivo pri bolnikih, ki imajo hude težave z ledvicami, pri bolnikih z obolenji jeter pa se lahko predpiše šele po skrbni oceni koristi in tveganj jemanja zdravila.
Cialis must not be used where sexual activity is inadvisable (e.g. in men with heart disease).
Zdravila ne smejo uporabljati osebe, ki jim je spolna aktivnost odsvetovana, na primer moški s srčnimi boleznimi.
By blocking the breakdown of cGMP, Cialis restores erectile function.
Z zaviranjem razgradnje cGMP zdravilo Cialis ponovno vzpostavi erektilno funkcijo, vendar je še vedno potrebna spolna stimulacija.
The maximum recommended dosing frequency is once per day, but continuous daily use of 10 or 20 mg Cialis is not recommended.
Odmerek se pri moških, ki se ne odzivajo na 10-miligramski odmerek, lahko poveča na 20 mg. Največja priporočena pogostost odmerjanja je enkrat na dan, vendar se odsvetuje dolgo trajajoče vsakodnevno jemanje 10 ali 20-miligramskega odmerka zdravila.
What is Cialis used for?
Za kaj se zdravilo Cialis uporablja?
How does Cialis work?
Kako zdravilo Cialis deluje?
How has Cialis been studied?
Kako je bilo zdravilo Cialis raziskano?
What is Cialis?
Kaj je zdravilo Cialis?
The dose is 5 mg once a day, but can be lowered to 2.5 mg once a day depending on how well it is tolerated.
Po presoji zdravnika se pri moških, ki ga nameravajo jemati bolj pogosto (dvakrat tedensko ali pogosteje), zdravilo lahko uporabi enkrat dnevno, vendar v manjšem odmerku, in sicer 5 mg enkrat na dan. Odmerek je mogoče znižati na 2,5 mg enkrat dnevno, odvisno od tega, kako
Cialis, when taken ‘on demand' before sexual activity, has been studied in six main studies including 1,328 patients with erectile dysfunction.
Zdravilo Cialis so proučevali v šestih glavnih študijah, v katerih je sodelovalo 1 328 bolnikov z erektilno disfunkcijo, ki so zdravilo vzeli „po potrebi“ pred spolno aktivnostjo.
How is Cialis used?
Kako se zdravilo Cialis uporablja?
The European Commission granted a marketing authorisation valid throughout the European Union for Trevaclyn to Merck Sharp & Dohme Ltd. on 3 July 2008.
Evropska Komisija je dovoljenje za promet z zdravilom Trevaclyn, veljavno po vsej Evropski uniji, odobrila družbi Merck Sharp & Dohme Ltd. dne 3. julija 2008.
Other information about Trevaclyn:
Druge informacije o zdravilu Trevaclyn:
Trevaclyn is not recommended for use in children under 18 years of age because of a lack of information on its safety and effectiveness in this group.
Zdravilo Trevaclyn ni priporočeno za zdravljenje otrok, starih manj kot 18 let, saj ni zadostnih informacij o varnosti in učinkovitosti v tej skupini.
The starting dose of Trevaclyn is one tablet once a day for four weeks, after which the dose is increased to two tablets once a day.
Začetni odmerek zdravila Trevaclyn je ena tableta enkrat dnevno štiri tedne, nato pa se odmerek poveča na dve tableti enkrat dnevno.
The Committee recommended that Trevaclyn be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Trevaclyn odobri dovoljenje za promet.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) TREVACLYN EPAR summary for the public
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) TREVACLYN Povzetek EPAR za javnost
What benefit has Trevaclyn shown during the studies?
Kakšne koristi je zdravilo Trevaclyn izkazalo med študijami?
The most common side effect with Trevaclyn (seen in more than 1 patient in 10) is flushing.
Najpogostejši neželeni učinek zdravila Trevaclyn (opažen pri več kot 1 bolniku od 10) je zardevanje.
Trevaclyn is used on its own only in patients who cannot take statins.
Zdravilo Trevaclyn se samostojno uporablja samo pri bolnikih, ki ne morejo jemati statina.
The effects of Trevaclyn were first tested in experimental models before being studied in humans.
Učinki zdravila Trevaclyn so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
What is the risk associated with Trevaclyn?
Kakšna tveganja so povezana z zdravilom Trevaclyn?
Two studies looked at the effectiveness of Trevaclyn in modifying blood fat levels.
Dve študiji sta preučevali učinkovitost zdravila Trevaclyn pri uravnavanju ravni maščob v krvi.
Trevaclyn is a medicine containing two active substances: nicotinic acid (also known as niacin or vitamin B3) and laropiprant.
Trevaclyn je zdravilo, ki vsebuje dve zdravilni učinkovini: nikotinsko kislino (znano tudi kot niacin ali vitamin B3) in laropiprant.
Trevaclyn was studied in four main studies in patients with hypercholesterolaemia or mixed dyslipidaemia.
Zdravilo Trevaclyn so raziskovali v štirih glavnih študijah pri bolnikih s hiperholesterolemijo ali mešano dislipidemijo.
The second study showed that the LDL cholesterol levels were further reduced when Trevaclyn was taken with simvastatin (48% reduction), compared with Trevaclyn alone (17% reduction) or simvastatin alone (37% reduction).
V drugi študiji so dokazali, da je prišlo še do večjega znižanja ravni LDL-holesterola v skupini, ki je jemala zdravilo Trevaclyn skupaj s simvastatinom (48 % znižanje), v primerjavi s tisto, ki je jemala zdravilo Trevaclyn samostojno (17 % znižanje) ali samo simvastatin (37 % znižanje).
They included a total of 2,349 patients who were taking either Trevaclyn or nicotinic acid.
Študiji sta vključevali vsega skupaj 2349 bolnikov, ki so jemali zdravilo Trevaclyn ali nikotinsko kislino.
In the first study, LDL cholesterol levels were reduced by 19% in patients taking Trevaclyn, compared with 1% in those taking placebo.
V prvi študiji so se ravni LDL pri bolnikih, ki so jemali zdravilo Trevaclyn, znižale za 19 % v primerjavi z 1 % pri tistih, ki so jemali placebo.
Trevaclyn is normally given together with a statin (the standard medicine used to reduce cholesterol) when the effectiveness of a statin taken alone is inadequate.
Zdravilo Trevaclyn se navadno daje skupaj s statinom (standardno zdravilo za zniževanje holesterola), kadar statin samostojno ni dovolj učinkovit.
Trevaclyn should not be used in people who may be hypersensitive (allergic) to nicotinic acid, laropiprant or any of the other ingredients.
Zdravila Trevaclyn ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) nikotinsko kislino, laropiprant ali katero koli drugo sestavino zdravila.
Why has Trevaclyn been approved?
Zakaj je bilo zdravilo Trevaclyn odobreno?
For the full list of all side effects reported with Trevaclyn, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Trevaclyn, glejte navodilo za uporabo.
Trevaclyn was effective in reducing the blood levels of LDL cholesterol.
Zdravilo Trevaclyn je bilo učinkovito pri zniževanju ravni LDL-holesterola.
The two active substances in Trevaclyn, nicotinic acid and laropiprant, have different modes of action.
Zdravilni učinkovini v zdravilu Trevaclyn, nikotinska kislina in laropiprant, imata različna načina delovanja.
The Committee for Medicinal Products for Human Use (CHMP) decided that Trevaclyn's benefits are greater than its risks for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia and in patients with primary hypercholesterolaemia.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Trevaclyn pri zdravljenju dislipidemije, zlasti pri bolnikih s kombinirano mešano dislipidemijo in bolnikih s primarno hiperholesterolemijo, večje od z njim povezanih tveganj.
The first study compared the effectiveness of Trevaclyn with that of nicotinic acid alone or placebo (a dummy treatment) in reducing the levels of LDL cholesterol in a total of 1,613 patients.
V prvi študiji so primerjali učinkovitost zdravila Trevaclyn s samostojno nikotinsko kislino ali placebom (zdravilom brez zdravilne učinkovine) pri zniževanju ravni LDL-holesterola pri vsega skupaj 1613 bolnikih.
In Trevaclyn tablets, laropiprant is in one of the layers, and the other layer contains nicotinic acid.
En sloj tablet zdravila Travaclyn vsebuje laropiprant, drugi sloj pa vsebuje nikotinsko kislino.
In the fourth study, flushing was seen on fewer days in patients taking Trevaclyn than in those taking nicotinic acid alone.
V četrti študiji je bilo število dni opaženega zardevanja manjše pri tistih bolnikih, ki so jemali zdravilo Trevaclyn kot pri tistih, ki so jemali samo nikotinsko kislino.
In the first and third studies, fewer patients taking Trevaclyn reported moderate, severe or extreme flushing than patients taking nicotinic acid alone.
V prvi in tretji študiji je o zmernem, hudem ali skrajnem zardevanju poročalo manj tistih bolnikov, ki so jemali Trevaclyn, kot tistih, ki so jemali samo nikotinsko kislino.
The nicotinic acid is released more slowly from the other layer and has its effect as a fat-modifying agent.
Nikotinska kislina se iz drugega sloja sprošča počasneje in učinkuje kot sredstvo za uravnavanje maščob v krvi.